Search
Lung Cancer Paid Clinical Trials in Pennsylvania
A listing of 133 Lung Cancer clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 48 of 133
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Lung Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Pennsylvania currently has 133 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
ā¢ Are at least 18 years old
ā¢ Have been unable to manage their high blood pressure with medications or lifestyle changes aloneĀ¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
Ā¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
ā¢ Are at least 18 years old
ā¢ Have been unable to manage their high blood pressure with medications or lifestyle changes aloneĀ¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
Ā¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
š 5 providers ranked by true monthly cost
šµ Options starting as low as $149/month
š„ Only licensed providers using FDA-registered pharmacies
ā Real Trustpilot scores included ā including the ones with mixed reviews
š Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
š 5 providers ranked by true monthly cost
šµ Options starting as low as $149/month
š„ Only licensed providers using FDA-registered pharmacies
ā Real Trustpilot scores included ā including the ones with mixed reviews
š Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Discover Clinical Trials In Your Area (Compensation Provided)
Recruiting
Clinical trials in your area are actively enrolling ā and they compensate you for your time. Finding the right one has never been easier.
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Type 1 Diabetes (T1DM) Clinical Study
Recruiting
A clinical study for people that suffer with Type 1 Diabetes (T1DM)
Conditions:
Type 1 Diabetes (T1DM)
Type 1 Diabetes
Diabetes Mellitus
Type 1
Type 1 Diabetes Mellitus (T1DM)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Alliance Cancer Specialists, Horsham, Pennsylvania
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
08/07/2025
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Pittsburgh, Pennsylvania +1 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Recruiting
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Non-small Cell Lung Cancer, Lung Cancer
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Recruiting
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion.
In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy.
In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Non-Small Cell Lung Cancer (NSCLC)
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Research Site, Horsham, Pennsylvania +1 locations
Conditions: Metastatic Non-small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: UPMC Hillman Cancer Center, Pittsburg, Pennsylvania
Conditions: Small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Recruiting
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency, Untreated Advanced NSCLC, 1st Line NSCLC
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Clinical Research Associates of Central PA, DuBois, Pennsylvania +4 locations
Conditions: Lung Cancer Diagnosis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/04/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania +2 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Recruiting
Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins) mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2025
Locations: Thomas Jefferson University Research Facility, Philadelphia, Pennsylvania
Conditions: Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
37 - 48 of 133